<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/PT-31-03-2026-shutterstock_1700459161-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/PT-31-03-2026-shutterstock_1700459161-430x241.jpg"/></p>
<p>CIB-301 通過完全人源化的 CAR scFv 靶向實體腫瘤。圖片來源：Vshivkova / Shutterstock.com。</p>
<p></p>
<p>uBriGene Biosciences 與 Cellinfinity BIO 簽署了戰略合作伙伴關係，以推進針對血液和實體腫瘤的體內嵌合抗原受體 T 細胞（CAR-T）療法的臨牀開發。</p>
<p>該合作伙伴關係專注於推進 Cellinfinity BIO 的 CIB-301 和 CIB-350 項目。</p>
<h3>深入瞭解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>LOA 和 PTSR 模型 - Idecabtagene Vicleucel 在多發性骨髓瘤中的應用</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>NPVM: Alaunos Therapeutics Inc 的腫瘤基因療法 2</h4>
<h5>深入瞭解 GlobalData</h5>
<p>商業智能的黃金標準。</p>
<p>瞭解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>發現高效的 B2B 營銷</h4>
<p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
<p>瞭解更多</p>
<p>uBriGene 的 LVV Turbo 平台將提供良好生產規範（GMP）下的慢病毒載體制造、生產、工藝開發和監管支持。</p>
<p>該平台整合了三項技術：完全封閉的下游純化過程、超增強劑和高產率的 293TH 懸浮細胞系。</p>
<p>在純化過程中可實現高達 80% 的回收率，並將 T 細胞轉導滴度提高五倍。</p>
<p>CIB-301 通過設計為低脱靶風險的完全人源化 CAR 單鏈可變片段（scFv）靶向實體腫瘤。</p>
<p>它針對與結直腸癌、子宮內膜癌、非小細胞肺癌、卵巢癌和腎細胞癌相關的腫瘤抗原。</p>
<p>CIB-350 採用雙特異性 CAR 設計，靶向自身免疫疾病和血液惡性腫瘤，能夠同時靶向兩個 B 細胞抗原。</p>
<p>uBriGene 提供集成的合同開發和製造組織（CDMO）及合同研究組織（CRO）服務，專注於細胞療法、病毒載體和核糖核酸（RNA）相關產品。</p>
<p>其全球 GMP 卓越中心支持客户開發下一代療法。</p>
<p>Cellinfinity BIO 的平台專注於對實體腫瘤進行精確的 T 細胞調節，旨在增強持久性和安全性，同時在臨牀前模型中展示抗腫瘤活性。</p>
<p>uBriGene 聯合創始人兼首席技術官 Dr. Sun Xiulian 表示：“我們對與 Cellinfinity Bio 的戰略合作伙伴關係感到興奮。體內 CAR-T 技術有潛力顯著降低治療成本。</p>
<p>“利用我們高產的 LVV Turbo 慢病毒載體平台和 GMP 製造專業知識，我們旨在降低 CAR-T 療法的商品成本，提高患者的可及性和負擔能力。”</p>
<p><em>Pharmaceutical Technology 上的細胞與基因療法報道由 Cytiva 支持。</em></p>
<p><em>編輯內容獨立製作，遵循</em> 最高標準 <em>的新聞誠信。主題贊助商不參與編輯內容的創作。</em></p>

2 倍做多納斯達克生物技術 ETF - ProShares

華夏恆生生物科技ETF(QDII)

納斯達克生物科技指數 ETF - iShares Nasdaq

<p>uBriGene Biosciences 已與 Cellinfinity BIO 達成合作，推進針對血液和實體腫瘤的體內 CAR-T 療法。此次合作重點關注 CIB-301 和 CIB-350 項目，利用 uBriGene 的 LVV Turbo 平台進行 GMP 慢病毒載體的生產。CIB-301 針對具有完全人源 CAR scFv 的實體腫瘤，而 CIB-350 則針對自身免疫疾病和血液惡性腫瘤。該合作旨在降低治療成本，提高患者對 CAR-T 療法的可及性</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/PT-31-03-2026-shutterstock_1700459161-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/PT-31-03-2026-shutterstock_1700459161-430x241.jpg"/></p>
<p>CIB-301 targets solid tumours using a fully human CAR scFv. Credit: Vshivkova / Shutterstock.com.</p>
<div class="lb-trans"><p>CIB-301 通過完全人源化的 CAR scFv 靶向實體腫瘤。圖片來源：Vshivkova / Shutterstock.com。</p>
</div><p></p>
<div class="lb-trans"><p></p>
</div><p>uBriGene Biosciences has signed a strategic partnership with Cellinfinity BIO to advance the clinical development of in vivo chimeric antigen receptor T-cell (CAR-T) therapy programmes for haematologic and solid tumours.</p>
<div class="lb-trans"><p>uBriGene Biosciences 與 Cellinfinity BIO 簽署了戰略合作伙伴關係，以推進針對血液和實體腫瘤的體內嵌合抗原受體 T 細胞（CAR-T）療法的臨牀開發。</p>
</div><p>The partnership focuses on progressing Cellinfinity BIO’s programmes CIB-301 and CIB-350.</p>
<div class="lb-trans"><p>該合作伙伴關係專注於推進 Cellinfinity BIO 的 CIB-301 和 CIB-350 項目。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入瞭解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>LOA and PTSR Model - Idecabtagene Vicleucel in Multiple Myeloma (Ka...</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - Idecabtagene Vicleucel 在多發性骨髓瘤中的應用</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>NPVM: Alaunos Therapeutics Inc's Gene Therapy 2 for Oncology</h4>
<div class="lb-trans"><h4>NPVM: Alaunos Therapeutics Inc 的腫瘤基因療法 2</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入瞭解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商業智能的黃金標準。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>發現高效的 B2B 營銷</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p>uBriGene’s LVV Turbo platform will provide good manufacturing practice (GMP) lentiviral vector manufacturing, production, process development, and regulatory support for these therapies.</p>
<div class="lb-trans"><p>uBriGene 的 LVV Turbo 平台將提供良好生產規範（GMP）下的慢病毒載體制造、生產、工藝開發和監管支持。</p>
</div><p>The platform integrates three technologies: a fully closed downstream purification process, the ultra-T enhancer, and a high-productivity 293TH suspension cell line.</p>
<div class="lb-trans"><p>該平台整合了三項技術：完全封閉的下游純化過程、超增強劑和高產率的 293TH 懸浮細胞系。</p>
</div><p>It achieves up to 80% recovery during purification and boosts T-cell transduction titres by five times.</p>
<div class="lb-trans"><p>在純化過程中可實現高達 80% 的回收率，並將 T 細胞轉導滴度提高五倍。</p>
</div><p>CIB-301 targets solid tumours with a fully human CAR single-chain variable fragment (scFv) designed for low off-target risk.</p>
<div class="lb-trans"><p>CIB-301 通過設計為低脱靶風險的完全人源化 CAR 單鏈可變片段（scFv）靶向實體腫瘤。</p>
</div><p>It addresses tumour antigens related to colorectal cancer, endometrial cancer, non-small cell lung cancer, ovarian cancer, and renal cell carcinoma.</p>
<div class="lb-trans"><p>它針對與結直腸癌、子宮內膜癌、非小細胞肺癌、卵巢癌和腎細胞癌相關的腫瘤抗原。</p>
</div><p>CIB-350 targets autoimmune diseases and haematologic malignancies with a bispecific CAR design able to target two B-cell antigens simultaneously.</p>
<div class="lb-trans"><p>CIB-350 採用雙特異性 CAR 設計，靶向自身免疫疾病和血液惡性腫瘤，能夠同時靶向兩個 B 細胞抗原。</p>
</div><p>uBriGene offers integrated contract development and manufacturing organisation (CDMO) and contract research organisation (CRO) services for cell therapies, viral vectors, and ribonucleic acid (RNA)-related products.</p>
<div class="lb-trans"><p>uBriGene 提供集成的合同開發和製造組織（CDMO）及合同研究組織（CRO）服務，專注於細胞療法、病毒載體和核糖核酸（RNA）相關產品。</p>
</div><p>Its global GMP Centers of Excellence support clients in developing next-generation therapies.</p>
<div class="lb-trans"><p>其全球 GMP 卓越中心支持客户開發下一代療法。</p>
</div><p>Cellinfinity BIO’s platforms focus on precise T-cell modulation for solid tumours, aiming to enhance persistence and safety while demonstrating anti-tumour activity in preclinical models.</p>
<div class="lb-trans"><p>Cellinfinity BIO 的平台專注於對實體腫瘤進行精確的 T 細胞調節，旨在增強持久性和安全性，同時在臨牀前模型中展示抗腫瘤活性。</p>
</div><p>uBriGene co-founder and CTO Dr Sun Xiulian said: “We are excited about this strategic partnership with Cellinfinity Bio. In vivo CAR-T technologies have the potential to significantly reduce treatment costs.</p>
<div class="lb-trans"><p>uBriGene 聯合創始人兼首席技術官 Dr. Sun Xiulian 表示：“我們對與 Cellinfinity Bio 的戰略合作伙伴關係感到興奮。體內 CAR-T 技術有潛力顯著降低治療成本。</p>
</div><p>“Leveraging our highly productive LVV Turbo lentiviral vector platform and GMP manufacturing expertise, we aim to lower the cost of goods for CAR-T therapies, improving patient accessibility and affordability.”</p>
<div class="lb-trans"><p>“利用我們高產的 LVV Turbo 慢病毒載體平台和 GMP 製造專業知識，我們旨在降低 CAR-T 療法的商品成本，提高患者的可及性和負擔能力。”</p>
</div><p><em>Cell &amp; Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva</em>.</p>
<div class="lb-trans"><p><em>Pharmaceutical Technology 上的細胞與基因療法報道由 Cytiva 支持。</em></p>
</div><p><em>Editorial content is independently produced and follows the</em> highest standards <em>of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.</em></p>
<div class="lb-trans"><p><em>編輯內容獨立製作，遵循</em> 最高標準 <em>的新聞誠信。主題贊助商不參與編輯內容的創作。</em></p>
</div>

uBriGene 與 Cellinfinity BIO 合作以加速體內 CAR-T 療法的發展